MSH2 germline loss-of-function in ovarian produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-MSH2-GERMLINE-OVARIAN |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Maladies | DIS-OVARIAN |
| Sources | SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-DMMR-IHC |
|---|---|
| Variante | MSH2 germline loss-of-function (dMMR / MSI-H) |
| Maladie | DIS-OVARIAN |
| Niveau ESCAT | IA |
| Combinaisons recommandées | pembrolizumab en monothérapie (pan-tumor MSI-H/dMMR, FDA 2017), traitement standard par CEU selon le statut HRD/BRCA |
| Résumé des faits | MSH2 germline loss-of-function in ovarian produces dMMR/MSI-H phenotype. Pan- tumor MSI-H ICI eligibility (pembrolizumab per KEYNOTE-158, dostarlimab per GARNET) supersedes tumor-specific lines via tissue-agnostic FDA approval. MSI-H is rare (~3%) in EOC; pembrolizumab tissue-agnostic applies in pretreated setting. |
Notes
Germline MSH2 loss → cascade testing mandatory (Lynch syndrome). Family meets Amsterdam/Bethesda criteria. Pan-tumor MSI-H ICI eligibility supersedes tumor- specific lines.
Utilisé par
No reverse references found in the YAML corpus.